GB0123571D0 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis - Google Patents

Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Info

Publication number
GB0123571D0
GB0123571D0 GBGB0123571.2A GB0123571A GB0123571D0 GB 0123571 D0 GB0123571 D0 GB 0123571D0 GB 0123571 A GB0123571 A GB 0123571A GB 0123571 D0 GB0123571 D0 GB 0123571D0
Authority
GB
United Kingdom
Prior art keywords
trifluoromethylphenyl
cyano
amide
hydroxy
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0123571.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23078354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0123571(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of GB0123571D0 publication Critical patent/GB0123571D0/en
Priority to US10/113,078 priority Critical patent/US6794410B2/en
Priority to AT02763962T priority patent/ATE396719T1/de
Priority to EP08004647A priority patent/EP1935416A3/en
Priority to ES02763962T priority patent/ES2305287T3/es
Priority to ARP020101245A priority patent/AR033459A1/es
Priority to SI200230727T priority patent/SI1381356T1/sl
Priority to DK02763962T priority patent/DK1381356T3/da
Priority to DE60226855T priority patent/DE60226855D1/de
Priority to PCT/US2002/010773 priority patent/WO2002080897A1/en
Priority to CA002443285A priority patent/CA2443285C/en
Priority to PT02763962T priority patent/PT1381356E/pt
Priority to EP02763962A priority patent/EP1381356B1/en
Priority to PA20028542901A priority patent/PA8542901A1/es
Priority to UY27244A priority patent/UY27244A1/es
Priority to HN2002000110A priority patent/HN2002000110A/es
Priority to CY20081100822T priority patent/CY1110446T1/el
Priority to CY2014004C priority patent/CY2014004I1/el
Priority to LU92366C priority patent/LU92366I2/fr
Priority to FR14C0010C priority patent/FR14C0010I2/fr
Priority to BE2014C008C priority patent/BE2014C008I2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0123571.2A 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis Ceased GB0123571D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
US10/113,078 US6794410B2 (en) 2001-04-05 2002-04-01 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP02763962A EP1381356B1 (en) 2001-04-05 2002-04-04 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP08004647A EP1935416A3 (en) 2001-04-05 2002-04-04 (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
CA002443285A CA2443285C (en) 2001-04-05 2002-04-04 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PT02763962T PT1381356E (pt) 2001-04-05 2002-04-04 Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
ES02763962T ES2305287T3 (es) 2001-04-05 2002-04-04 Uso de (4'-trifluorometifenil)-amida del acido (z)-ciano-3-hidroxi-but-2-enoico para tratar la esclerosis multiple.
ARP020101245A AR033459A1 (es) 2001-04-05 2002-04-04 Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
SI200230727T SI1381356T1 (sl) 2001-04-05 2002-04-04 Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
DK02763962T DK1381356T3 (da) 2001-04-05 2002-04-04 Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
DE60226855T DE60226855D1 (de) 2001-04-05 2002-04-04 Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
PCT/US2002/010773 WO2002080897A1 (en) 2001-04-05 2002-04-04 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
AT02763962T ATE396719T1 (de) 2001-04-05 2002-04-04 Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
PA20028542901A PA8542901A1 (es) 2001-04-05 2002-04-05 Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
UY27244A UY27244A1 (es) 2001-04-05 2002-04-05 Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
HN2002000110A HN2002000110A (es) 2001-04-05 2002-05-08 Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
CY20081100822T CY1110446T1 (el) 2001-04-05 2008-08-06 Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοϊκου οξεος-(4’-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια πολλαπλης σκληρωσης
CY2014004C CY2014004I1 (el) 2001-04-05 2014-01-23 Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοϊκου οξεος-(4’-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια πολλαπλης σκληρωσης
LU92366C LU92366I2 (fr) 2001-04-05 2014-01-29 Teriflunomide, son stéréoisomère et leurs sels pharmaceutiquement acceptables
FR14C0010C FR14C0010I2 (fr) 2001-04-05 2014-02-05 Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques
BE2014C008C BE2014C008I2 (OSRAM) 2001-04-05 2014-02-13

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28168501P 2001-04-05 2001-04-05

Publications (1)

Publication Number Publication Date
GB0123571D0 true GB0123571D0 (en) 2001-11-21

Family

ID=23078354

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0123571.2A Ceased GB0123571D0 (en) 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Country Status (6)

Country Link
US (2) US6794410B2 (OSRAM)
BE (1) BE2014C008I2 (OSRAM)
CY (1) CY1110446T1 (OSRAM)
EC (1) ECSP024244A (OSRAM)
GB (1) GB0123571D0 (OSRAM)
HN (1) HN2002000110A (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR245601A0 (en) 2001-01-10 2001-02-01 Silverbrook Research Pty Ltd An apparatus (WSM09)
CA2673398A1 (en) * 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
EP2277515A1 (en) 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
MX336663B (es) * 2009-09-18 2016-01-27 Sanofi Sa Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada.
MX2012004348A (es) 2009-10-22 2012-05-22 Sanofi Aventis Us Llc Uso de la combinacion de teriflunomida y acetato de glatiramer para tratar la esclerosis multiple.
EP2314291A1 (en) 2009-10-22 2011-04-27 Sanofi-Aventis Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
AR081220A1 (es) 2010-05-26 2012-07-04 Sanofi Aventis Us Llc Uso de teriflunomida para el tratamiento de la atrofia cerebral
AR081764A1 (es) 2010-05-26 2012-10-17 Sanofi Aventis Us Llc Uso de teriflunomida para mantener el nivel de fatiga de un paciente que tiene esclerosis multiple, articulo de fabricacion y envase
EP2600861A1 (en) 2010-08-02 2013-06-12 Sanofi-Aventis U.S. LLC Use of teriflunomide for treating multiple sclerosis
US8957098B2 (en) 2010-08-24 2015-02-17 Algiax Pharmaceuticals Gmbh Use of leflunomide and malononitrilamides
WO2012061060A1 (en) 2010-10-25 2012-05-10 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating brain atrophy
WO2012061062A1 (en) 2010-10-25 2012-05-10 Sanofi-Aventis U.S. Llc Use of teriflunomide for improving motor function
DK2632451T3 (en) * 2010-10-29 2017-12-18 Algiax Pharmaceuticals Gmbh USE OF MALONNITRILAMIDS IN NEUROPATHIC PAIN
AR085305A1 (es) 2011-02-24 2013-09-18 Sanofi Aventis Us Llc Uso de la teriflunomida para el tratamiento del deterioro cognitivo
WO2012162339A1 (en) 2011-05-24 2012-11-29 Sanofi-Aventis U.S. Llc Use of teriflunomide for reducing occurrence of relapses requiring healthcare resources
RU2471482C1 (ru) * 2011-10-27 2013-01-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
EP2762135A1 (en) 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US4284784A (en) * 1980-05-22 1981-08-18 Merck & Co., Inc. Process for the preparation of 4-methyl thiazole
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4965278A (en) * 1989-04-21 1990-10-23 Warner-Lambert Company 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
IT1254519B (it) 1992-03-16 1995-09-25 Chiesi Farma Spa Associazioni di composti ad attivita' antivirale
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19534649A1 (de) 1995-09-19 1997-03-20 Hoechst Ag 2-Cyano-3-mercaptocrotonsäureamide
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US5856330A (en) 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US6011051A (en) 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
DE59800287D1 (de) 1997-08-08 2000-11-09 Aventis Pharma Gmbh Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19857009A1 (de) 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
WO2001060363A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide

Also Published As

Publication number Publication date
US6794410B2 (en) 2004-09-21
ECSP024244A (es) 2002-08-01
BE2014C008I2 (OSRAM) 2021-02-04
CY1110446T1 (el) 2015-04-29
US20020177623A1 (en) 2002-11-28
US20030223960A1 (en) 2003-12-04
HN2002000110A (es) 2002-07-04

Similar Documents

Publication Publication Date Title
SI1381356T1 (sl) Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
GB0123571D0 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
IL178864A0 (en) 3'-prodrugs of 2'-deoxy-??-l-nucleosides
EP1452919A4 (en) POSITIVE RESIST COMPOSITION AND METHOD OF FORMING THE RESIST PATTERN
PL373301A1 (en) Phosphodiesterase 4 inhibitors
ITMI20022234A1 (it) Apparecchiatura e procedimento per l'esecuzione di codifica
PL353535A1 (en) Application of selective pde 10 inhibitor and application of papaverine
EP1452918A4 (en) POSITIVE RESERVE COMPOSITION AND METHOD OF FORMING RESIST PATTERN
IL159538A0 (en) 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
HRPK20040615B3 (en) Parenteral composition of paracetamol
NO20025964D0 (no) Ny interferon for behandling av multippel sklerose
AU2003298664A8 (en) Treatment of cognitive dysfunctions'
IL163926A0 (en) Crystal structure of phosphodiesterase 5 and use thereof
PL370315A1 (en) Use of desoxypeganine for treating clinical depression
GB0114231D0 (en) Treatment of multiple sclerosis
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU2002338344A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP1385821A4 (en) NEW ANTI-ADHESIVE CONNECTIONS AND USES THEREFOR
GB0113343D0 (en) Novel Heterocycles 2
EP1414427A4 (en) KAVALACTONE COMPOSITIONS AND METHODS OF USE
GB0118670D0 (en) Distribution of information
AP2007003992A0 (en) 3'-Prodrugs of 2'-deoxy-beta-l-nucleosides
ITMI20011484A0 (it) Metodo per il rivestimento di particelle ed apparecchiatura per l'attuazione di esse
SI1448564T1 (sl) Substituirane indolizinu podobne spojine in postopki uporabe
TW585273U (en) Base structure of backlight mask

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)